Evidence map›Paper›PMID 40787462›Full record

ArticleFrontiers in immunology2025

Mechanistic insights into promotion of non-small cell lung cancer by BAG5 using integrative multi-omics approaches.

Jing-Shan Huang, Jia-Mei Wang, Ye Yuan, Ting Zhang, Bai-Qiang Li, Fu-Ying Zhao, Liang Hao, Zhan-Wu Yu, Hua-Qin Wang

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jing-Shan HuangDepartment of Thoracic Surgery, the Shengjing Hospital, China Medical University, Shenyang, China.
Jia-Mei WangDepartment of Laboratory Medicine, The 1st Affiliated Hospital, China Medical University, Shenyang, China.
Ye YuanDepartment of Biochemistry & Molecular Biology, China Medical University, Shenyang, China.
Ting ZhangDepartment of Biochemistry & Molecular Biology, China Medical University, Shenyang, China.
Bai-Qiang LiDepartment of Biochemistry & Molecular Biology, China Medical University, Shenyang, China.
Fu-Ying ZhaoDepartment of Biochemistry & Molecular Biology, China Medical University, Shenyang, China.
Liang HaoDepartment of Chemistry, School of Forensic Medicine, China Medical University, Shenyang, China.
Zhan-Wu YuDepartment of Thoracic Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.
Hua-Qin WangDepartment of Biochemistry & Molecular Biology, China Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: With the continuous emergence of new technologies in omics, the integrative analysis of multi-omics data has become a new direction to explore life mechanisms. The Bcl-2 associated athanogene (BAG) family consists of co-chaperones involved in various cellular processes, including stress signaling, cell cycle regulation, and tumorigenesis. BAG5, a unique member of this family, contains multiple BAG domains, yet its role in non-small cell lung cancer (NSCLC) remains largely unexplored. Methods: In this study, we employed a multi-omics approach, integrating single-cell transcriptomics, proteomics, interactomics, and phosphoproteomics data to comprehensively investigate BAG5 function in NSCLC. Functional analyses were performed using cell lines and patient-derived organoids (PDOs) to validate our findings. Results: Our results demonstrate that BAG5 plays a critical role in the regulation of RNA metabolism, mitochondrial dynamics, and metabolic reprogramming. Additionally, BAG5 is involved in cytoskeletal remodeling and epithelial-to-mesenchymal transition (EMT), contributing to the proliferation and invasion of NSCLC cells. Discussion: These findings underscore the potential oncogenic role of BAG5 in NSCLC, revealing that it acts through multiple molecular pathways. Our study suggests that targeting BAG5 could be a promising therapeutic strategy for treating NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsCell Line, TumorCell ProliferationEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansMultiomicsProteomicsBAG5EMTmetabolic reprogrammingmulti-omicsNSCLC

Identifiers

PMID40787462
PMCPMC12331601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.